Related Experiment Video
Updated: May 12, 2026
Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling
Published on: March 20, 2026
Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule
Antonella Chillemi1, Gianluca Zaccarello, Valeria Quarona
1Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino Medical School, Torino, Italy.
Abstract:
In vivo use of monoclonal antibodies (mAbs) has become a mainstay of routine clinical practice in the treatment of various human diseases. A number of molecules can serve as targets, according to the condition being treated. Now entering human clinical trials, CD38 molecule is a particularly attractive target because of its peculiar pattern of expression and its twin role as receptor and ectoenzyme. This review provides a range of analytical perspectives on the current progress in and challenges to anti-CD38 mAb therapy. We present a synopsis of the evidence available on CD38, particularly in myeloma and chronic lymphocytic leukemia (CLL). Our aim is to make the data from basic science helpful and accessible to a diverse clinical audience and, at the same time, to improve its potential for in vivo use. The topics covered include tissue distribution and signal implementation by mAb ligation and the possibility of increasing cell density on target cells by exploiting information about the molecule's regulation in combination with drugs approved for in vivo use. Also analyzed is the behavior of CD38 as an enzyme: CD38 is a component of a pathway leading to the production of adenosine in the tumor microenvironment, thus inducing local anergy. Consequently, not only might CD38 be a prime target for mAb-mediated therapy, but its functional block may contribute to general improvement in cancer immunotherapy and outcomes.
Insights
Anti-CD38 monoclonal antibody (mAb) therapy shows promise for treating cancers like myeloma and CLL. Targeting CD38 may enhance cancer immunotherapy and improve patient outcomes by blocking its enzymatic activity.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Monoclonal antibodies (mAbs) are integral to treating human diseases.
- CD38 is an emerging target for mAb therapy due to its unique expression and dual function.
- CD38 plays a role in the tumor microenvironment by producing adenosine, leading to immune suppression.
Purpose of the Study:
- To review the progress and challenges in anti-CD38 mAb therapy.
- To highlight the therapeutic potential of targeting CD38 in hematological malignancies.
- To bridge basic science findings with clinical applications for anti-CD38 mAbs.
Main Methods:
- Review of existing scientific literature on CD38 and mAb therapy.
- Analysis of CD38 expression patterns and its role as a receptor and enzyme.
- Exploration of strategies to enhance anti-CD38 mAb efficacy in vivo.
Main Results:
- CD38 is a validated target in myeloma and chronic lymphocytic leukemia (CLL).
- Anti-CD38 mAb therapy can be optimized by understanding CD38 regulation and combining with other drugs.
- Blocking CD38's enzymatic activity may reverse tumor-induced immune suppression.
Conclusions:
- Anti-CD38 mAb therapy holds significant potential for cancer treatment.
- Targeting CD38 can improve outcomes in hematological malignancies and potentially other cancers.
- Further research into CD38's enzymatic function could unlock new immunotherapy strategies.
